AC Immune SA (NASDAQ:ACIU) announces new preclinical data on its next-generation alpha-synuclein positron emission tomography-(PET) tracer. The results were presented virtually at the Alzheimer’s Association International Conference.
The company says the data showed enhanced contrast and alpha-synuclein target specificity, positioning the tracer to become a first-in-class precision diagnostic tool for Parkinson’s disease (PD).
Alpha-synuclein misfolding, aggregation and seeding are the molecular basis for the formation of Lewy bodies, a hallmark of PD, multiple system atrophy, and Lewy body dementia.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.